Screener
Beam Therapeutics BEAM Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current liabilities | 74,565 | 96,935 |
| Long-term lease liability | 135,848 | 139,759 |
| Long-term portion of contingent consideration liabilities | 5,449 | 5,952 |
| Long-term portion of debt | 100,193 | — |
| Other liabilities | 305 | 173 |
| Total liabilities | 316,360 | 242,819 |
| Commitments and contingencies (See Note 7, License and other agreements and Note 8, Collaboration and license agreements) | ||
| Stockholders’ equity: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's long-term debt?
- Beam Therapeutics (BEAM) reported long-term debt of $100.19M in Q1 2026.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Beam Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude